A peer-reviewed article just published in the Annals of Medicine titled “Multi-tiered screening and diagnosis strategy for COVID-19: a model for sustainable testing capacity in response to pandemic” describes an algorithm for sustainable testing capacity to efficiently evaluate patients in response to a pandemic.
The multi-tiered, diagnostic strategy incorporates a rapid host immune response assay (such as FebriDx®) as a screening test, molecular confirmatory testing, and rapid IgM/IgG testing (such as COV-ID™) to assess benefit from quarantine/further testing and provide information on population exposure/herd immunity.
- Click here to access the study.
New Study Highlights the Utility of the FebriDx® Test for Rapid Triage and Identification of COVID-19
Lumos Diagnostics today announced the publication of a COVID-19 (SARS-CoV-2) clinical trial in The International Journal of Clinical Practice. Kettering General Hospital in the UK prospectively performed a clinical assessment of the FebriDx® point-of-care (POC) fingerstick blood test to rapidly assess and differentiate viral from bacterial symptomatic respiratory infections. The study concluded that FebriDx could be deployed as part of a reliable triage strategy for identifying symptomatic cases as possible COVID-19 in the pandemic.